HOUSTON, Jan. 5, 2018 /PRNewswire/ -- RadiaDyne® announces issuance of US Patent 9,833,637, a skin patch dosimeter, whichrelates to the monitoring of skin radiation dose delivered during cancer treatment. "This issuance of this patent provides broad protection for our unique sensor delivery devices for skin applications related to the OARtrac patient radiation dose monitoring
ABOUT THE OARTRAC PLATFORM. OARtrac® is the first of its kind patient dose monitoring platform which provides gold standard accuracy, real-time pinpoint measurement, and proprietary intracavitary delivery devices to measure physical dose during radiation treatment. OARtrac® provides critical radiation dose feedback which helps facilitate adaptive radiotherapy with the goal to reduce side effects and offer better clinical outcomes.
ABOUT RADIADYNE: RadiaDyne® is a privately held diagnostic and medical device company focused on patient dose monitoring technology to improve cancer treatment outcomes. RadiaDyne designs and innovates specialized sensor technology and medical treatment devices which assist Radiation Oncologists in delivering radiation dose to the cancerous targets, while minimizing damage to the surrounding healthy tissue.
View original content:http://www.prnewswire.com/news-releases/radiadyne-receives-skin-device-patent-for-the-oartrac-patient-radiation-dose-monitoring-system-300578305.html
Subscribe to our Free Newsletters!
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...View All